Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Orally delivered drugs pharmacokinetics

As an oral, triple pro-drug, capecitabine has been designed to deliver specifically 5-FU in tumor cells, and as such its pharmacokinetics profile should not be strongly affected by erratic DPD activity in the liver (36). Nevertheless, because the enzymes supporting final activation of capecitabine can be expressed in hepatocytes too, early synthesis of 5-FU may occur in the liver, thus leading eventually to plasma overexposure, as confirmed by a physiologically-based PK model (37). [Pg.253]

Comparative pharmacokinetic profiles of nifedipine delivered from Procardia XL, an osmotic pressure-controlled drug delivery system, once-a-day versus that from Procardia, an immediate-release dosage form, taken on time 0, 8 and 16 in human volunteers. Modified from Y.W. Chien. Oral drug delivery and delivery systems. Y.W.Chien (ed.) (1992) Novel Drug Delivery Systems. Marcel Dekker, Inc. New York, pp. 139-196... [Pg.161]

Molecules which are permanently ionised (e.g. quaternary ammonium salts) can be quite acceptable drugs in special circumstances, such as drugs which are to be administered i.v., but for drugs aimed to be delivered orally, such permanent ionisation will confer poor pharmacokinetic properties. Hence knowledge of the ionisation pattern (pKa constants) will be required. Monoacids and monobases with pKa values in the range of 3-10 would be a... [Pg.31]

Unlike intravascular dosage forms, in which a solution of drug is injected (usually by the intravenous route) into the systemic circulation, extravascular dosage forms are not immediately delivered into the systemic circulation. Extravascular dosage forms such as oral, intramuscular, subcutaneous and transdermal patches are meant to deliver dmg to the systemic circulation however, this systemic delivery is not instantaneous. Therefore, the pharmacokinetic equations require a term reflecting an absorption process. In order to understand multiple oral dosing, one... [Pg.243]

These observations were interesting because many potential drug candidates cannot be delivered orally due to their poor pharmacokinetics. This includes the poor solubility and dissolution of the drug in the intestinal lumen, poor permeation properties in the gastrointestinal (GI) tract, as well as high intestinal or hepatic first-pass metabolism. It is estimated that more than 95 % of new drug molecules suffer from these kinds of problems in bioavailability (Brayden 2003). [Pg.113]


See other pages where Orally delivered drugs pharmacokinetics is mentioned: [Pg.193]    [Pg.191]    [Pg.193]    [Pg.107]    [Pg.5]    [Pg.27]    [Pg.321]    [Pg.150]    [Pg.4]    [Pg.315]    [Pg.182]    [Pg.145]    [Pg.511]    [Pg.2066]    [Pg.135]    [Pg.470]    [Pg.338]    [Pg.355]    [Pg.302]    [Pg.163]    [Pg.523]    [Pg.201]    [Pg.591]    [Pg.201]    [Pg.415]    [Pg.275]    [Pg.254]    [Pg.504]   
See also in sourсe #XX -- [ Pg.172 , Pg.181 ]




SEARCH



Drug pharmacokinetic

Drugs pharmacokinetics

Oral drugs

Oral pharmacokinetics

Orally delivered drugs

Pharmacokinetics oral drugs

© 2024 chempedia.info